The FDA issued a new draft guidance to industry for developing plans to enroll more participants from underrepresented racial and ethnic populations in the U.S. into clinical trials – expanding on the agency’s previous guidances for industry to improve clinical trial diversity.
Read more: FDA Takes Important Steps to Increase Racial and Ethnic Diversity in Clinical Trials